X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the termination, AC Immune will regain all global rights to the anti-amyloid beta antibody RO5490245 (crenezumab) and the anti-Tau antibody semorinemab. Both antibodies have been evaluated in clinical studies for Alzheimer’s disease (AD).
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: RO5490245
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $418.0 million Upfront Cash: Undisclosed
Deal Type: Termination January 22, 2024
Details:
MABT5102A (crenezumab) is a passive immunotherapy approach in which patients are treated with monoclonal antibodies that specifically recognize Aβ peptides. This humanized antibody uses an IgG4 backbone.
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: MABT5102A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022
Details:
As previously reported, numerical differences favoring MABT5102A (crenezumab) over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistically significant.
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: MABT5102A
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
The trial did not demonstrated significant benefit in either of its co-primary endpoints, for MABT5102A (crenezumab) ability to slow or prevent Alzheimer’s disease in people with a specific genetic mutation after five to eight years of treatment compared with placebo.
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: MABT5102A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
The trial did not demonstrated significant clinical benefit in either of its co-primary endpoints, evaluating ability of MABT5102A (crenezumab) to treat Alzheimer’s disease in people with specific genetic mutation after five to eight years of treatment compared with placebo.
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: MABT5102A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
Crenezumab (MABT5102A), is an investigational, monoclonal antibody designed to neutralise neurotoxic oligomers, a form of beta-amyloid. Crenezumab has an antibody backbone (IgG4) designed to minimise the inflammatory response in the brain.
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: MABT5102A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Banner Alzheimer’s Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
